Robert G. Hahn
About
In The Last Decade
Robert G. Hahn
455 papers receiving 8.4k citations
Peers
Comparison fields: 5 of 167
- Surgery 3.9k
- Pulmonary and Respiratory Medicine 2.4k
- Critical Care and Intensive Care Medicine 2.1k
- Cardiology and Cardiovascular Medicine 1.8k
- Urology 1.8k
Countries citing papers authored by Robert G. Hahn
This map shows the geographic impact of Robert G. Hahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert G. Hahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert G. Hahn more than expected).
Fields of papers citing papers by Robert G. Hahn
This network shows the impact of papers produced by Robert G. Hahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert G. Hahn. The network helps show where Robert G. Hahn may publish in the future.
Co-authorship network of co-authors of Robert G. Hahn
This figure shows the co-authorship network connecting the top 25 collaborators of Robert G. Hahn. A scholar is included among the top collaborators of Robert G. Hahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert G. Hahn. Robert G. Hahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 10 | |
| 5 | 6 | |
| 6 | 5 | |
| 7 | 0 | |
| 8 | 3 | |
| 9 | 0 | |
| 10 | 6 | |
| 11 | 17 | |
| 12 | 27 | |
| 13 | 55 | |
| 14 | 4 | |
| 15 | Physiological or Functional Fluid Spaces [2] (muliple letters) | 2 |
| 16 | Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. | 24 |
| 17 | Evaluation of a fixed alternating treatment in patients with advanced breast cancer. | 9 |
| 18 | Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. | 20 |
| 19 | Phase II study of chromomycin A3 (NSC-58514) in advanced colorectal carcinoma. | 2 |
| 20 | Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. | 54 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.